Lyfebulb, the company co-founded by <strong>Dr. Karin Hehenberger PhD</strong>, with <strong>Dr. Steve Squinto</strong>, Venture partner Orbimed and <strong>Riccardo Braglia</strong>, CEO Helsinn, is about to launch an early-stage Autoimmune Disease / Diabetes Innovation Venture Fund. The Scientific Advisory Board is chaired by <strong>Robert Langer PhD</strong>, David H. Koch Institue, MIT.<br /> <br /> Focused on breakthrough opportunities in autoimmune, insulin-dependent diabetes and other associated autoimmune diseases. Our goals are to deliver a superior return on investment.